In fact, in recent years, new and effective therapeutic options involving the use of drug agents targeting CTLA-4, PD-1, and PD-L1 were developed against several solid tumors, including melanoma, renal cell carcinoma (RCC), and non-small cell lung cancer (NSCLC) [20,21,22,23,24]. This evidence concerns the gene CTLA4 and renal cell carcinoma.